49 related articles for article (PubMed ID: 20594369)
1. Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings.
Forster M; Bailey C; Brinkhof MW; Graber C; Boulle A; Spohr M; Balestre E; May M; Keiser O; Jahn A; Egger M;
Bull World Health Organ; 2008 Dec; 86(12):939-47. PubMed ID: 19142294
[TBL] [Abstract][Full Text] [Related]
2. The determinants of HIV treatment costs in resource limited settings.
Menzies NA; Berruti AA; Blandford JM
PLoS One; 2012; 7(11):e48726. PubMed ID: 23144946
[TBL] [Abstract][Full Text] [Related]
3. Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficiencies.
Shattock AJ; Benedikt C; Bokazhanova A; Đurić P; Petrenko I; Ganina L; Kelly SL; Stuart RM; Kerr CC; Vinichenko T; Zhang S; Hamelmann C; Manova M; Masaki E; Wilson DP; Gray RT
PLoS One; 2017; 12(2):e0169530. PubMed ID: 28207809
[TBL] [Abstract][Full Text] [Related]
4. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.
Paltiel AD; Zheng A; Weinstein MC; Gaynes MR; Wood R; Freedberg KA; Sax PE; Walensky RP
Open Forum Infect Dis; 2017; 4(2):ofx081. PubMed ID: 28680903
[TBL] [Abstract][Full Text] [Related]
5. Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.
Ramautarsing R; Ananworanich J
AIDS Res Ther; 2010 Jun; 7():18. PubMed ID: 20569473
[TBL] [Abstract][Full Text] [Related]
6. A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa.
Leisegang R; Maartens G; Hislop M; Sargent J; Darkoh E; Cleary S
PLoS One; 2013; 8(2):e53570. PubMed ID: 23405073
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme.
Boyles TH; Wilkinson LS; Leisegang R; Maartens G
PLoS One; 2011 May; 6(5):e19201. PubMed ID: 21559280
[TBL] [Abstract][Full Text] [Related]
8. Scaling up health policies and services in low- and middle-income settings.
Hanson K; Cleary S; Schneider H; Tantivess S; Gilson L
BMC Health Serv Res; 2010 Jul; 10 Suppl 1(Suppl 1):I1. PubMed ID: 20594366
[No Abstract] [Full Text] [Related]
9. The lifetime cost of current human immunodeficiency virus care in the United States.
Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of statistically-derived models of immunological response in HIV-infected adults on antiretroviral therapy in Sub-Saharan Africa.
Sempa JB; Ujeneza EL; Nieuwoudt M
PLoS One; 2017; 12(2):e0171658. PubMed ID: 28199360
[TBL] [Abstract][Full Text] [Related]
11. Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings.
Leisegang R; Maartens G; Hislop M; Regensberg L; Cleary S
BMC Health Serv Res; 2010 Jul; 10 Suppl 1(Suppl 1):S3. PubMed ID: 20594369
[TBL] [Abstract][Full Text] [Related]
12. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis.
Leisegang R; Cleary S; Hislop M; Davidse A; Regensberg L; Little F; Maartens G
PLoS Med; 2009 Dec; 6(12):e1000189. PubMed ID: 19956658
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
15. SESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa.
Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Achieng B; Sepeka M; Tlali K; Sao L; Thin K; Klimkait T; Battegay M; Labhardt ND
BMC Infect Dis; 2018 Feb; 18(1):76. PubMed ID: 29433430
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
